Loading data for HROW — first visit, this takes a few seconds.

알림

Harrow Inc. (HROW)

NasdaqGM: HROW · 실시간 가격 · USD

36.59

-0.68 (-1.82%)

종가 기준: Aug 28, 2026, 3:59 PM

37.72

+1.21%

프리마켓: 4:00 AM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-1.82% (1D)

매수호가	28.48
시가총액	1.4B
매출 (ttm)	275.59M
순이익 (ttm)	-37.23M
	0.25
	-0.99
	n/a
	13.62
P/B (ttm)	91.80
P/S (ttm)	5.07
실적 발표일	Nov 9, 2026

매도호가	51.2
거래량	57,670
평균 거래량 (20일)	658,276
시가	37.22
전일 종가	37.27
일중 범위	36.28 - 37.45
52주 범위	28.54 - 54.85
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

HROW 소개

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as B...

섹터 Healthcare

IPO 일자 Sep 28, 2007

직원 수 373

상장 거래소 NasdaqGM

티커 HROW

웹사이트 https://www.harrow.com

전체 기업 정보

재무 실적

2025년 Harrow의 매출은 272.3M로, 전년 199.61M 대비 36.41% 증가했습니다. 순이익은 -5.14M로, -70.6% 감소했습니다.

재무제표

어닝 서프라이즈

Harrow가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $44.2M 예상치 하회 $0, 및 -7.59% 전년 대비 감소.
EPS -0.46 예상치 하회 -0.22, 및 -291.67% 전년 대비 감소.

다음 실적 발표

Harrow Inc.의 실적 발표 예정일은 Nov 9, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Insider Monkey

Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target

On August 10, Harrow Inc. (NASDAQ:HROW) walked investors through a first half that fell short and a back half that now has to make up the difference. Revenue for the first six months of 2026 came in a...

1주 전 · Motley Fool

Harrow (HROW) Q2 2026 Earnings Call Transcript

Revenue hit $70.7M with guidance raised to $350M-$365M for full year.

2주 전 · Insider Monkey

Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?

According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. U...

2주 전 · Simply Wall St.

Harrow (HROW) Adds New Eye Care Firepower With Product Launch And Acquisition

Harrow (NasdaqGM:HROW) announced the launch of BYOOVIZ in the retinal biosimilar market, adding a new product to its ophthalmology lineup. The company reported expanded formulary coverage for VEVYE, i...

2주 전 · GuruFocus.com

Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ...

Harrow Inc (HROW) reports strong Q2 2026 with record IHISO and Vevi demand, reiterates full-year guidance, and outlines accretive Tervaya acquisition synergies.

2 페이지 중 1